ALCHEMIST - A081105: Randomized Study of Erlotinib vs Observation in patients with completely resected epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer(NSCLC)

About this Study

The purpose of this research study is to examine lung cancer patients' surgically removed tumors for certain genetic changes, and to possibly refer these patients to a treatment study with drugs that may specifically target tumors that have these genetic changes. 

Sponsor Protocol ID:A081105
IRB Number:2015-0238
Actively Enrolling
Observational
Phase 3
July 30, 2019
Eligibility Criteria
18 years old
100 years old
Both Male and Female
Yes
No
Yes

Inclusion CriteriaThe purpose of this research study is to examine lung cancer patients' surgically removed tumors for certain genetic changes, and to possibly refer these patients to a treatment study with drugs that may specifically target tumors that have these genetic changes. 

Categories Click category to view its trials.
Cancer
Lungs/Breathing
Participating Locations
Cancer Center and Research Institute
University Hospital
Contact Information
Contact Name: Jennifer Barnes
Phone Number: 601-815-4540
Email: jbarnes@umc.edu
Principal Investigator:Ruckdeschel, John C, M.D.
How to participate in our Clinical Trials